Treatment of cancer metastasis by targeting exosome proteins
The present disclosure provides a therapeutic method of treating cancer metastasis by inducing clearance of EVs using a binding agent specific to an EV protein. The method utilizes one or more binding agents specific to EV proteins, where the EV proteins are selected from prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4); CD13 (aminopeptidase N); MME (neprilysin), ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase family member 1); and NRP1 (neuropilin-1). Further provided herein includes a pharmaceutical composition for the treatment of cancer metastasis.
1 . A method of treating cancer metastasis comprising:
a. collecting blood from a subject with cancer;
b. treating the blood ex vivo with an effective amount of a binding agent that specifically binds to extracellular vesicles (EVs) expressing an EV protein, wherein the EV protein is prostaglandin F2 receptor negative regulator (PTGFRN);
c. removing the EVs expressing the EV protein to reduce a concentration of the EVs expressing the EV protein in the blood;
d. measuring the concentration of the EVs expressing the EV protein in the blood; and
e. reinfusing the blood to the subject.
2 . The method of claim 1 , wherein the concentration of the EVs expressing the EV protein in the blood is reduced by at least 10%.
3 . The method of claim 1 , wherein the subject has metastatic cancer.
4 . The method of claim 3 , further comprising measuring metastasis rates of the cancer in the subject.
5 . The method of claim 1 , wherein the EV protein is expressed on EVs released from cancer cells of the subject.
6 . The method of claim 1 , wherein the binding agent binds to the EV protein with a KD of less than 50 nM.
7 . The method of claim 1 , wherein the binding agent comprises an antigen binding protein (ABP).
8 . The method of claim 7 , wherein the binding agent comprises an antibody, antibody fragment, scFab, or scFv.
9 . The method of claim 8 , wherein the binding agent is a divalent or a multivalent antibody or antibody fragment.
10 . The method of claim 8 , wherein the binding agent is a human, humanized, or chimeric antibody or antibody fragment.
11 . The method of claim 1 , further comprising administering to the subject a second binding agent that specifically binds to a second EV protein, wherein the second EV protein is selected from the group consisting of: prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-I (ITGB I); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); and ATP transporter protein.
12 . The method of claim 11 , wherein the administration of the second binding agent is performed concurrently with the administration of the binding agent.
13 . The method of claim 11 , wherein the administration of the second binding agent is performed separately from the administration of the binding agent.
14 . The method of claim 11 , wherein the binding agent and the second binding agent are different.
15 . The method of claim 1 , further comprising evaluating tumor size in the subject.
16 . The method claim 1 , wherein the blood and the binding agent are incubated for at least 10 minutes.
17 . The method claim 1 , wherein the EVs expressing the EV protein in the blood are removed using immunoadsorption technologies.